ArticleBMC public health2023
Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.
Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.Clinical pharmacology and therapeutics · 2026Trial
- The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor.Journal of psychopharmacology (Oxford, England) · 2024Trial
- [Psychiatric aspects of commercially available products containing cannabidiol].Der Nervenarzt · 2026Review
- Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.British journal of clinical pharmacology · 2026Article
- Differences in Cannabis and Cannabidiol Attitudes, Perceptions, and Behaviors Between US Adolescents Receiving Mood Disorder Treatment and Their Parents Across Legal Contexts.International journal of environmental research and public health · 2025Article
- Beyond the hype - who uses cannabidiol for self-medication - and why: a cross-sectional study in Germany.Journal of cannabis research · 2025Article
- Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co-Use: Results From the European Web Survey on Drugs.Drug and alcohol review · 2025Article
- Treatment demand for cannabis use problems: analyses of routine data from 30 European countries.European archives of psychiatry and clinical neuroscience · 2025Article
- Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.Nutrients · 2025Review
- Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey.Parkinson's disease · 2025Article
- Over the counter CBD products in Germany: an exploratory survey about consumption patterns and health related effects.Frontiers in pharmacology · 2025Article
- Prevalence of cannabidiol use and correlates in U.S. adults.Drug and alcohol dependence reports · 2024Article
- Updated Risk Assessment of Cannabidiol in Foods Based on Benchmark Dose-Response Modeling.Molecules (Basel, Switzerland) · 2024Review
- Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson's disease: A French survey.Clinical parkinsonism & related disorders · 2024Article
- Cannabidiol Use Among Older Adults: Associations with Cannabis Use, Physical and Mental Health, and Other Substance Use.Clinical gerontologistArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabidiol (CBD), a non-intoxicating substance of Cannabis sativa L., is gaining consumer attention. Yet, legal regulations in the EU are complex and questions of potential health risks remain partly unanswered. In Germany, little is known about people who use CBD products. The aim of this cross-sectional study was to gain insight into the user group of CBD, reasons for consumption and risk perception towards CBD-containing products.
methodsThe study consisted of two parts: In the first part of the study, the prevalence of CBD awareness and usage in Germany was estimated using a telephone survey and a population-representative sample of n = 1,011 respondents. Based on these results, n = 2,000 participants being aware of CBD were surveyed with an online questionnaire in the second part of the study to examine usage and perception of CBD in users and non-users.
resultsWhen the study was conducted at the end of 2020 and beginning of 2021, 40.2% of the German participants had already heard of products containing CBD, and 11.4% had actually used them. 42.1% of the users consumed such products regularly, at least once a week, primarily orally via oils or tinctures, and purchased them mainly online. Besides curiosity - addressed especially in young adults - anticipated health benefits including pain and stress relief were main reasons for use. More than half of the study participants perceived the health benefits of CBD use as high or very high. In contrast, the health risks were rated as low or very low by most respondents. Assumptions about official testing for safety as well as physical effects of CBD-containing products varied between users and non-users.
conclusionAbout one in nine people in Germany uses CBD-containing products. Given reasons for consumption and perception of potential health risks and benefits suggest that people are insufficiently informed about CBD-containing products. The results of the study indicate that risk communication is needed to raise awareness for the topic and to inform (potential) users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.